0001567619-21-008228.txt : 20210416
0001567619-21-008228.hdr.sgml : 20210416
20210416164957
ACCESSION NUMBER: 0001567619-21-008228
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210416
FILED AS OF DATE: 20210416
DATE AS OF CHANGE: 20210416
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Disbrow Joshua R.
CENTRAL INDEX KEY: 0001566240
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38247
FILM NUMBER: 21832131
MAIL ADDRESS:
STREET 1: AMPIO PHARMACEUTICALS, INC.
STREET 2: 5445 DTC PARKWAY, SUITE 925
CITY: GREENWOOD VILLAGE
STATE: CO
ZIP: 80111
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AYTU BIOPHARMA, INC
CENTRAL INDEX KEY: 0001385818
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 470883144
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: 373 INVERNESS PARKWAY
STREET 2: SUITE 206
CITY: ENGLEWOOD
STATE: CO
ZIP: 80112
BUSINESS PHONE: (720) 437-6580
MAIL ADDRESS:
STREET 1: 373 INVERNESS PARKWAY
STREET 2: SUITE 206
CITY: ENGLEWOOD
STATE: CO
ZIP: 80112
FORMER COMPANY:
FORMER CONFORMED NAME: AYTU BIOSCIENCE, INC
DATE OF NAME CHANGE: 20150609
FORMER COMPANY:
FORMER CONFORMED NAME: AYTU BIOSCIENCE, INC.
DATE OF NAME CHANGE: 20150609
FORMER COMPANY:
FORMER CONFORMED NAME: Rosewind CORP
DATE OF NAME CHANGE: 20070110
4
1
doc1.xml
FORM 4
X0306
4
2021-04-16
0
0001385818
AYTU BIOPHARMA, INC
AYTU
0001566240
Disbrow Joshua R.
C/O AYTU BIOPHARMA, INC.
373 INVERNESS PARKWAY, SUITE 206
ENGLEWOOD
CO
80112
1
1
0
0
Chief Executive Officer
Common Stock
2021-04-16
4
A
0
800000
0
A
897506
D
Grant of restricted shares. The restricted shares have the following accelerated vesting conditions: (1) The consummation of a Sale Event. (2) The closing price of the Company's stock price is equal or greater than forty dollars per share ($40) for two consecutive trading days. (3) The Grantee's service with the Company or a Related Entity is terminated by the Company without Cause (as defined below). (4) At the Compensation Committee's discretion based on the Company achieving certain revenue milestones and the successful integration of future acquisitions. The restricted shares vest as follows, and have no voting or dispositive rights until vested: 1/3 on April 16, 2022, and 1/12 on the first day of each quarter thereafter, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continuing employment with the Issuer.
/s/Joshua R. Disbrow
2021-04-16